WallStSmart

Ubiquiti Networks Inc (UI)vsCommScope Holding Company, Inc. (VISN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Ubiquiti Networks Inc generates 54% more annual revenue ($2.97B vs $1.93B). VISN leads profitability with a 118.2% profit margin vs 29.9%. UI appears more attractively valued with a PEG of 0.82. UI earns a higher WallStSmart Score of 73/100 (B).

UI

Strong Buy

73

out of 100

Grade: B

Growth: 9.3Profit: 10.0Value: 5.3Quality: 7.3
Piotroski: 5/9Altman Z: 5.14

VISN

Buy

58

out of 100

Grade: C

Growth: 5.3Profit: 7.0Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

UIFair Value (-4.0%)

Margin of Safety

-4.0%

Fair Value

$685.62

Current Price

$839.05

$153.43 premium

UndervaluedFair: $685.62Overvalued
VISNSignificantly Overvalued (-153.9%)

Margin of Safety

-153.9%

Fair Value

$7.55

Current Price

$18.48

$10.93 premium

UndervaluedFair: $7.55Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

UI6 strengths · Avg: 9.8/10
Return on EquityProfitability
136.1%10/10

Every $100 of equity generates 136 in profit

Operating MarginProfitability
35.9%10/10

Strong operational efficiency at 35.9%

Revenue GrowthGrowth
35.8%10/10

Revenue surging 35.8% year-over-year

EPS GrowthGrowth
70.8%10/10

Earnings expanding 70.8% YoY

Altman Z-ScoreHealth
5.1410/10

Safe zone — low bankruptcy risk

Market CapQuality
$50.50B9/10

Large-cap with strong market position

VISN4 strengths · Avg: 9.0/10
Profit MarginProfitability
118.2%10/10

Keeps 118 of every $100 in revenue as profit

Revenue GrowthGrowth
50.6%10/10

Revenue surging 50.6% year-over-year

P/E RatioValuation
16.0x8/10

Attractively priced relative to earnings

Operating MarginProfitability
29.1%8/10

Strong operational efficiency at 29.1%

Areas to Watch

UI2 concerns · Avg: 2.0/10
P/E RatioValuation
57.0x2/10

Premium valuation, high expectations priced in

Price/BookValuation
50.0x2/10

Trading at 50.0x book value

VISN3 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

PEG RatioValuation
2.942/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : UI

The strongest argument for UI centers on Return on Equity, Operating Margin, Revenue Growth. Profitability is solid with margins at 29.9% and operating margin at 35.9%. Revenue growth of 35.8% demonstrates continued momentum.

Bull Case : VISN

The strongest argument for VISN centers on Profit Margin, Revenue Growth, P/E Ratio. Profitability is solid with margins at 118.2% and operating margin at 29.1%. Revenue growth of 50.6% demonstrates continued momentum.

Bear Case : UI

The primary concerns for UI are P/E Ratio, Price/Book. A P/E of 57.0x leaves little room for execution misses.

Bear Case : VISN

The primary concerns for VISN are EPS Growth, Return on Equity, PEG Ratio.

Key Dynamics to Monitor

VISN carries more volatility with a beta of 2.46 — expect wider price swings.

VISN is growing revenue faster at 50.6% — sustainability is the question.

UI generates stronger free cash flow (259M), providing more financial flexibility.

Monitor COMMUNICATION EQUIPMENT industry trends, competitive dynamics, and regulatory changes.

Bottom Line

UI scores higher overall (73/100 vs 58/100), backed by strong 29.9% margins and 35.8% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ubiquiti Networks Inc

TECHNOLOGY · COMMUNICATION EQUIPMENT · USA

Ubiquiti Inc. develops network technology for service providers, businesses and consumers. The company is headquartered in New York, New York.

CommScope Holding Company, Inc.

TECHNOLOGY · COMMUNICATION EQUIPMENT · USA

Gyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company, develops gene therapy products to treat patients with eye diseases. The company is headquartered in Stevenage, the United Kingdom.

Want to dig deeper into these stocks?